Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Trend Edge rates GTBP Bearish with a Setup Score of 37, net conviction 33, actionability 42. How the Setup Score works →
| Total Setup Score | 37 |
|---|---|
| Directional Bias | Bearish |
| Net Conviction | 33 |
| Actionability | 42 (in range) |
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that t… Read full Trend Edge analysis →
| Current Price | $4.32 |
|---|---|
| Market Cap | $9.4M |
| Float | 1.5M |
| Shares Outstanding | 2.1M |
| P/E (Forward) | 17.33 |
| Price/Sales (TTM) | 204.96 |
| vs. Analyst Target | +1636.1% to analyst PT |
| Dividend Rate | None |
| Analyst Target Price | $75.00 (1 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2020 | N/A | -$28.3M | N/A | -$25.0M |
| 2021 | N/A | -$58.0M | N/A | -$57.5M |
| 2022 | N/A | -$20.9M | N/A | -$21.0M |
| 2023 | N/A | -$7.6M | N/A | $6.0M |
| 2024 | N/A | -$13.2M | N/A | -$13.2M |
| 2025 | N/A | -$28.4M | N/A | -$28.2M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Sep 2025 | N/A | $8.3M |
| Dec 2025 | N/A | -$23.0M |
| Mar 2026 | N/A | -$2.8M |
| Jun 2026 | N/A | -$4.5M |
| Insider Ownership | 10.3% |
|---|---|
| Institutional Ownership | 8.0% |
| Short Float | 18.0% |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $6.20 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $8.95 | Medium-term trend |
| Weekly | 80-Week SMA | $21.63 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $108.36 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $8.47 | Near-term monthly trend |
| Monthly | 20-Month SMA | $22.76 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $63.61 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $16.20 | resistance | 1.21x | 8 months ago |
| $23.20 | resistance | 1.70x | 13 months ago |
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | -0.45% | -0.36% | 38.24% | 20.22% | -18.02% |
| 1 Day | 1.17% | 0.20% | 50.00% | 33.33% | -25.41% |
| 1 Week | 3.71% | 0.87% | 55.88% | 44.09% | -23.45% |
| 2 Weeks | -0.31% | -3.23% | 35.29% | 51.56% | -35.52% |
| 1 Month | 67.31% | -5.53% | 35.29% | 2421.89% | -45.59% |
Next earnings: November 13, 2026 (3 days away)
| Month | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Jan | -4.5% | 50.0% | 8 |
| Feb | -15.8% | 25.0% | 8 |
| Mar | 1.5% | 37.5% | 8 |
| Apr | -2.4% | 33.3% | 9 |
| May | 13.4% | 66.7% | 9 |
| Jun | 1.9% | 55.6% | 9 |
| Jul | -9.7% | 22.2% | 9 |
| Aug | -12.2% | 11.1% | 9 |
| Sep | -15.6% | 11.1% | 9 |
| Oct | 2.8% | 66.7% | 9 |
| Nov | -13.3% | 12.5% | 8 |
| Dec | 3.7% | 37.5% | 8 |
| Day | Avg Return | Win Rate | Samples |
|---|---|---|---|
| Monday | -0.04% | 42.0% | 407 |
| Tuesday | 0.22% | 45.6% | 445 |
| Wednesday | -0.51% | 40.2% | 443 |
| Thursday | -0.28% | 42.4% | 436 |
| Friday | 0.14% | 46.3% | 434 |
Institutional holder breakdown coming soon.
Total institutional ownership: 8.0%
Total insider ownership: 10.3%
Full insider transaction history and smart buy/sell sentiment summary available on Trend Edge.
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for GT Biopharma Inc (GTBP) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for GTBP on Trend Edge →